These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
90 related items for PubMed ID: 15651713
1. Efficacy of lumiracoxib in osteoarthritis: a review of nine studies. Berenbaum F, Grifka J, Brown JP, Zacher J, Moore A, Krammer G, Dutta D, Sloan VS. J Int Med Res; 2005; 33(1):21-41. PubMed ID: 15651713 [Abstract] [Full Text] [Related]
2. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo. Sheldon E, Beaulieu A, Paster Z, Dutta D, Yu S, Sloan VS. Clin Ther; 2005 Jan; 27(1):64-77. PubMed ID: 15763607 [Abstract] [Full Text] [Related]
3. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib. Fleischmann R, Sheldon E, Maldonado-Cocco J, Dutta D, Yu S, Sloan VS. Clin Rheumatol; 2006 Feb; 25(1):42-53. PubMed ID: 16132165 [Abstract] [Full Text] [Related]
4. First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215]. Wittenberg RH, Schell E, Krehan G, Maeumbaed R, Runge H, Schlüter P, Fashola TO, Thurston HJ, Burger KJ, Trechsel U. Arthritis Res Ther; 2006 Feb; 8(2):R35. PubMed ID: 16469112 [Abstract] [Full Text] [Related]
5. Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib. Lehmann R, Brzosko M, Kopsa P, Nischik R, Kreisse A, Thurston H, Litschig S, Sloan VS. Curr Med Res Opin; 2005 Apr; 21(4):517-26. PubMed ID: 15899100 [Abstract] [Full Text] [Related]
6. Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies. Schnitzer TJ, Gitton X, Jayawardene S, Sloan VS. Curr Med Res Opin; 2005 Jan; 21(1):151-61. PubMed ID: 15881487 [Abstract] [Full Text] [Related]
7. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. Tannenbaum H, Berenbaum F, Reginster JY, Zacher J, Robinson J, Poor G, Bliddal H, Uebelhart D, Adami S, Navarro F, Lee A, Moore A, Gimona A. Ann Rheum Dis; 2004 Nov; 63(11):1419-26. PubMed ID: 15020310 [Abstract] [Full Text] [Related]
8. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial. Schnitzer TJ, Beier J, Geusens P, Hasler P, Patel SK, Senftleber I, Gitton X, Moore A, Sloan VS, Poór G. Arthritis Rheum; 2004 Aug 15; 51(4):549-57. PubMed ID: 15334426 [Abstract] [Full Text] [Related]
9. Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand. Grifka JK, Zacher J, Brown JP, Seriolo B, Lee A, Moore A, Gimona A. Clin Exp Rheumatol; 2004 Aug 15; 22(5):589-96. PubMed ID: 15485012 [Abstract] [Full Text] [Related]
10. Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis. Dougados M, Moore A, Yu S, Gitton X. Arthritis Res Ther; 2007 Aug 15; 9(1):R11. PubMed ID: 17266764 [Abstract] [Full Text] [Related]
11. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis. Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan VS, Olson M, Mellein B, Hoexter G, Orloff J, Garaud JJ. Clin Ther; 2005 Aug 15; 27(8):1196-214. PubMed ID: 16199245 [Abstract] [Full Text] [Related]
12. Lumiracoxib. Lyseng-Williamson KA, Curran MP. Drugs; 2004 Aug 15; 64(19):2237-46; discussion 2247-8. PubMed ID: 15456339 [Abstract] [Full Text] [Related]
13. A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis. Schnitzer TJ, Dattani ID, Seriolo B, Schneider H, Moore A, Tseng L, Sallstig P, Rebuli R, Maxwell T. Clin Rheumatol; 2011 Nov 15; 30(11):1433-46. PubMed ID: 21607551 [Abstract] [Full Text] [Related]
14. Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis. Fleischmann R, Tannenbaum H, Patel NP, Notter M, Sallstig P, Reginster JY. BMC Musculoskelet Disord; 2008 Mar 07; 9():32. PubMed ID: 18328090 [Abstract] [Full Text] [Related]
15. Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain. Kellstein D, Ott D, Jayawardene S, Fricke J. Int J Clin Pract; 2004 Mar 07; 58(3):244-50. PubMed ID: 15117090 [Abstract] [Full Text] [Related]
19. Predictors of response to cyclo-oxygenase-2 inhibitors in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib, and placebo. Bingham CO, Smugar SS, Wang H, Peloso PM, Gammaitoni A. Pain Med; 2011 Mar 07; 12(3):352-61. PubMed ID: 21332932 [Abstract] [Full Text] [Related]
20. Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis. Hawkey CC, Svoboda P, Fiedorowicz-Fabrycy IF, Nasonov EL, Pikhlak EG, Cousin M, Gitton X, Hoexter G. J Rheumatol; 2004 Sep 07; 31(9):1804-10. PubMed ID: 15338504 [Abstract] [Full Text] [Related] Page: [Next] [New Search]